CD274 and cancer: Interestingly, positive correlations were observed between expression levels of most of these genes and the signature of PD-L1 (Figure S2A), indicating that targeting these genes in clinical cancer treatment might also suppress expression or effects of PD-L1, an important immune checkpoint expressed in cancer cells.